“The extension of the single role to AIFA's scientific officers, approved with an amendment, will allow the Agency to prevent the flight of high-profile professionals, while maintaining high attractiveness in view of an increase in staff”.

This is how the president of the Italian Medicines Agency, Robert Nisticò, comments on the approval of the single role for scientific officers, provided for in the Budget Law 2025. In the light of the absolute incompatibilities in force at the Agency, the legislation will allow AIFA's scientific officers to benefit from the exclusivity indemnity on a par with their colleagues employed by the SSN and the Ministry of Health.

“A decisive step forward towards the Agency's efficiency” Nisticò continues “obtained thanks to the sensitivity of the Ministry of Economy and Finance and of the State General Accounting Department in particular, which have understood the strategic value of AIFA, which regulates, with its decisions on prices and reimbursement of medicines, a market with a production value of 50 billion euro. An activity” he concludes “which, with the forthcoming application of the European HTA Regulation, will entail a greater commitment by the Agency's staff and heads, but also greater revenue for the services rendered”.

AIFA's president thanks “the Minister of Health, for his attention, and the Government, as well as the Economy Legislative Office and the State General Accounting Department for their consideration and valuable technical support”.